Sort
15,273 grants matching “antimicrobial resistance”
Salt-Sensitive Hypertension: Role of renal superoxide
$745,559Jeffrey L. Garvin · Case Western Reserve University · R01 · FY2025 · HL
Transcriptional Profiling to Discriminate Bacterial and Non-bacterial Respiratory Illnesses
$745,477Ann R Falsey · University Of Rochester · R01 · FY2022 · AI
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
$745,427Ryan Bock · Sintx Technologies, Inc. · R44 · FY2025 · AR
Molecular Mechanisms of Inflammation, Steatosis and Hepatic Insulin Resistance
$745,195Jerrold M Olefsky · University Of California, San Diego · R24 · FY2011 · DK
Advancement of poxvirus inhibitor
$745,122John H Connor · Boston University Medical Campus · R01 · FY2024 · AI
The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
$745,067Ebbing Lautenbach · University Of Pennsylvania · R01 · FY2019 · AI
EpiModel 2.0: Integrated Network Models for HIV/STI Prevention Science
$744,465Samuel Jenness · Emory University · R01 · FY2019 · AI
Population Genomic Analysis of Gut Microbial Colonization in Premature Infants
$744,269Jillian Banfield · University Of California Berkeley · R01 · FY2025 · AI
Novel Drug Discovery against P. falciparum ENR
$744,131James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2008 · AI
Molecular Clonality of Uropathogenic E. Coli
$744,078Evgeni Veniaminovic Sokurenko · University Of Washington · R01 · FY2023 · AI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging
$744,062Sanjay Jain · Johns Hopkins University · R01 · FY2021 · AI
Development of validated probes for the bacterial type III secretion system
$743,821Victoria Auerbuch Stone · University Of California Santa Cruz · R01 · FY2022 · AI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)
$743,796Pavimol Angsantikul · Population Council · R01 · FY2024 · AI
HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating
$743,507Carine Nkemngong · Halomine, Inc. · R44 · FY2024 · AI
Human coronavirus infection of the nasal epithelium
$743,489Susan R. Weiss · University Of Pennsylvania · R01 · FY2023 · AI
A Next-Generation Scalable Platform to Discover Antimicrobials of Ribosomal Origin
$743,463Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2024 · AI
A Next-Generation Scalable Platform to Discover Antimicrobials of Ribosomal Origin
$743,463Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2025 · AI
Cooperation and antagonism in polymicrobial infection
$743,284Daniel J Wozniak · Ohio State University · R01 · FY2024 · AI
Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experiment
$743,157Sara Tartof · Kaiser Foundation Research Institute · R01 · FY2020 · AI
Optimization of novel pyranopyridine efflux pump inhibitors
$742,587Timothy J Opperman · Microbiotix, Inc · R44 · FY2017 · AI
RNAi-dependent epimutation roles in antimicrobial drug resistance and pathogenesis
$742,324Joseph Heitman · Duke University · R01 · FY2023 · AI
Cefixime Dose-Response in the Mouse Model of Neisseria gonorrhoeae infection
$742,216National Institute Of Allergy And Infectious Diseases · Y01 · FY2016 · AI
Integrated Platform for the Discovery of Antibacterial
$741,949Suzanne L. Walker · Harvard Medical School · U19 · FY2016 · AI
Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
$741,917Mariette Barbier · West Virginia University · R01 · FY2024 · AI
Early life antibiotics, gut microbiome development, and risk of childhood obesity
$741,895Jeffrey Stephen Gerber · Children'S Hosp Of Philadelphia · R01 · FY2018 · AI